February, 1998

• An FDA memo concludes that Roche "had not acted in good faith to truly and accurately answer questions relating to Accutane use in women and pregnancy exposure." The memo recommends, "active consideration of removal of Accutane from the market." The memo also concludes that: "Given all the pieces of evidence available, it is difficult to avoid the conclusion that Accutane can adversely affect the adult human brain in clinically significant ways and that Accutane use is associated with severe psychiatric disease in some patients."

17

Kathryn O'Connell, M.D.